Umactin 25 mg/5 ml (Oral Suspension)
100 ml bottle: ৳ 80.00
Medicine Details
Category | Details |
---|---|
Generic | Nitrofurantoin |
Company | Unimed unihealth pharmaceuticals ltd |
Also available as |
Indications
- Treatment of urinary tract infections
- Prophylaxis of urinary tract infections
- Targeted bacteria strains
Pharmacology
- Antibacterial agent for urinary tract infections
- Highly soluble in urine
- Inactivates or alters bacterial ribosomal proteins
- Active against specific bacteria strains
Dosage
- Different dosage forms for adults and children
- Recommended dosages for different conditions
- Dosage adjustments for long-term therapy
Administration
- Should be taken with food
Interaction
- Interacts with antacids containing Magnesium Trisilicate
- Inhibits renal tubular secretion of certain drugs
Contraindications
- Anuria, oliguria, or significant renal impairment
- Contraindicated in pregnant patients at 38-42 weeks, during labor and delivery
- Known hypersensitivity to Nitrofurantoin
Side Effects
- Frequent adverse events: nausea, headache, flatulence
- Less common adverse events: diarrhea, dyspepsia, abdominal pain, constipation, emesis, dizziness, drowsiness
Pregnancy & Lactation
- Pregnancy Category B
- Use during pregnancy only if clearly needed
- Detected in human breast milk in trace amounts
Precautions & Warnings
- Discontinue if pulmonary reactions occur
- Avoid antacid preparations containing magnesium trisilicate
Overdose Effects
- Acute overdosage results in vomiting
- Induction of emesis recommended
Therapeutic Class
- Systemic Urinary Anti-infective
Storage Conditions
- Do not store above 30°C
- Keep away from light and out of the reach of children
Related Brands
- Uritro 25 mg/5 ml (Oral Suspension) - team-pharmaceuticals-ltd
- Furabac 100 mg (Capsule (Sustained Release)) - popular-pharmaceuticals-ltd
- NFT 25 mg/5 ml (Oral Suspension) - healthcare-pharmaceuticals-ltd
- NFT 100 mg (Capsule (Sustained Release)) - healthcare-pharmaceuticals-ltd
- Urobak SR 100 mg (Capsule (Sustained Release)) - opsonin-pharma-ltd